In this randomized trial, dalbavancin didn't result in improved outcomes versus standard treatment for adults with complicated Staphylococcus aureus bacteremia. Rates of adverse events leading to ...

Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 and DISCOVER 2 were ...

Please provide your email address to receive an email when new articles are posted on . Dalbavancin requires two doses 7 days apart, compared with standard 4- to 8-week therapy for S. aureus ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A two-dose regimen of dalbavancin — a long-acting ...

CHICAGO (AP) -- Durata Therapeutics Inc. said Monday its antibiotic dalbavancin met its goal in another late-stage clinical trial. The company said dalbavancin worked as well as vancomycin, an older ...

The US Food and Drug Administration (FDA) has approved the antibacterial agent dalbavancin (Dalvance, Durata Therapeutics) for treatment of adults with skin infections, including methicillin-resistant ...

Earlier this month, Durata submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (:EMA) for dalbavancin seeking approval for the marketing and sale of dalbavancin ...

A new addition to Fresenius Kabi’s anti-infective portfolio, Dalbavancin for Injection is indicated for acute bacterial skin and skin structure infections and approved for single-dose regimen use only ...

Dalbavancin (Dalvance) didn't deliver better overall outcomes compared with standard treatment in adults with complicated Staphylococcus aureus bacteremia, a randomized trial showed. Among 200 ...